非小细胞肺癌组织硫氧还蛋白还原酶表达及预后分析

被引：6

作者：

张文利

孙开宇

谭强

刁秀芳

刘婷

机构：

[1] 潍坊市人民医院呼吸内科

来源：

中华肿瘤防治杂志 | 2016年 / 23卷 / 18期

关键词：

肺肿瘤; 免疫组织化学; 硫氧还蛋白还原酶; 预后;

D O I：

10.16073/j.cnki.cjcpt.2016.18.004

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

目的硫氧还蛋白还原酶（thioredoxin reductase,TrxR）是肿瘤相关性蛋白,其在肿瘤细胞的增殖和分化中起着重要的作用。本研究探讨TrxR在非小细胞肺癌（non-small cell lung cancer,NSCLC）中的表达及对预后的影响。方法免疫组化法检测潍坊市人民医院胸外科2013-02-01-10-30 87例NSCLC组织和20例癌旁正常组织中TrxR的表达,分析其与临床病理参数之间的关系,并随访患者生存时间进行分析。结果肺癌组织TrxR阳性率为93.1%（81/87）,癌旁组织中阳性率为20.0%（4/20）,差异有统计学意义,χ2=52.710,P<0.01。低分化癌组织TrxR表达高于中、高分化癌组织,差异有统计学意义,χ2=11.876,P=0.03。有淋巴结转移组TrxR表达高于无淋巴结转移组,差异有统计学意义,χ2=5.471,P=0.02。TNM分期中ⅢⅣ期TrxR的表达明显高于Ⅰ、Ⅱ期中的表达,差异有统计学意义,χ2=4.711,P=0.03。TrxR的表达水平与患者的性别、年龄、吸烟史和病理分型无明显相关性。Kaplan-Meier生存分析结果显示,TrxR高表达组患者预后更差,χ2=6.467,P=0.01。多因素Cox回归分析显示,TrxR是危险因素,P<0.01。结论 TrxR在NSCLC中高表达并提示预后不良。

引用

页码：1224 / 1228

页数：5

共 12 条

[1]

Increased expression levels of E-cadherin, cytokeratin 18 and 19 observed in preeclampsia were not correlated with disease severity [J].

Li, X. L. ;

Dong, X. ;

Xue, Y. ;

Li, C. F. ;

Gou, W. L. ;

Chen, Q. .

PLACENTA, 2014, 35 (08) :625-631

[2]

EXPRESSION OF THIOREDOXINS AND GLUTAREDOXINS IN HUMAN HEPATOCELLULAR CARCINOMA: CORRELATION TO CELL PROLIFERATION, TUMOR SIZE AND METABOLIC SYNDROME [J].

Mollbrink, A. ;

Jawad, R. ;

Vlamis-Gardikas, A. ;

Edenvik, P. ;

Isaksson, B. ;

Danielsson, O. ;

Stal, P. ;

Fernandes, A. P. .

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 (02) :169-183

[3]

TrxR1 and GPx2 are potently induced by isothiocyanates and selenium, and mutually cooperate to protect Caco-2 cells against free radical-mediated cell death [J].

Barrera, Lawrence N. ;

Cassidy, Aedin ;

Wang, Wei ;

Wei, Taotao ;

Belshaw, Nigel J. ;

Johnson, Ian T. ;

Brigelius-Flohe, Regina ;

Bao, Yongping .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (10) :1914-1924

[4]

Biological evaluation of novel selenazole-based compounds as potential thioredoxin reductase inhibitors [J].

Li, Dong-Dong ;

He, Jie ;

Zeng, Hui-Hui .

APPLIED ORGANOMETALLIC CHEMISTRY, 2012, 26 (11) :619-624

[5]

Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy [J].

He, Jie ;

Li, Dongdong ;

Xiong, Kun ;

Ge, Yongjie ;

Jin, Hongwei ;

Zhang, Guozhou ;

Hong, Mengshi ;

Tian, Yongliang ;

Yin, Jin ;

Zeng, Huihui .

BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (12) :3816-3827

[6]

Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.[J].Lihui Wang;Zhiyu Yang;Jianing Fu;Hanwei Yin;Kun Xiong;Qiang Tan;Hongwei Jin;Jing Li;Tianyu Wang;Wanchen Tang;Jin Yin;Gaoxiong Cai;Mi Liu;Sebastian Kehr;Katja Becker;Huihui Zeng.Free Radical Biology and Medicine.2011, 5

[7]

Statins inhibit expression of Thioredoxin reductase 1 in rat and human liver and reduce tumour development.[J]..Biochemical and Biophysical Research Communications.2011, 3

[8]

Increased expression of thioredoxin-1; vascular endothelial growth factor; and redox factor-1 is associated with poor prognosis in patients with liver metastasis from colorectal cancer.[J].Terumasa Noike;Shiro Miwa;Junpei Soeda;Akira Kobayashi;Shin-ichi Miyagawa.Human Pathology.2008, 2

[9]

Thioredoxin in cancer - Role of histone deacetylase inhibitors [J].